Moderna's stock dropped 10% following a strong rally driven by its personalized cancer vaccine progress. The decline is seen as profit taking ahead of a critical late-stage melanoma trial data release expected later this month. Moderna's oncology efforts, particularly the intismeran autogene vaccine combined with Keytruda, have fueled recent gains, with multiple ongoing trials in various cancers. Investors await full data at the European Society for Medical Oncology meeting to confirm earlier positive results, while Moderna's commercial vaccine business remains stable but less of a growth driver.
As of Oct 16, 2026 22:02 WIB, Moderna (MRNA) trades at USD 215.97, down 8.68% on Pluang, retreating from its 52-week high of USD 236.50 but still far above its low of USD 22.36. BioNTech (BNTX) also eased slightly by 1.19% to USD 89.13, closer to its 52-week low of USD 83.89 than its high of USD 119.34. Meanwhile, Pfizer (PFE) remains steady with a modest 0.54% gain at USD 29.60, supported by a dividend yield of 5.84% and a longer typical hold time of 158 days on Pluang.
Moderna shares surged 6% amid a broader market rotation from AI and tech stocks into healthcare, outperforming peers BioNTech and Pfizer. This rally is supported by positive clinical data from August showing Moderna's personalized mRNA cancer vaccine...
Moderna's stock has surged over 650% this year due to excitement around its personalized cancer vaccine showing promising trial results. Despite this rally, analyst price targets remain much lower than the current share price, suggesting the stock ma...
